Shares of Petmed Express Inc (NASDAQ:PETS) have been assigned an average recommendation of “Sell” from the six brokerages that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

Separately, BidaskClub upgraded Petmed Express from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd.

PETS traded down $0.07 on Wednesday, hitting $17.70. 498,182 shares of the company were exchanged, compared to its average volume of 659,179. Petmed Express has a 12 month low of $16.93 and a 12 month high of $46.83. The firm has a market cap of $350.67 million, a price-to-earnings ratio of 9.27 and a beta of 0.66.

Petmed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.14). The business had revenue of $64.57 million during the quarter, compared to the consensus estimate of $69.06 million. Petmed Express had a return on equity of 28.96% and a net margin of 13.32%. Petmed Express’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.50 earnings per share.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 17th were given a $0.27 dividend. The ex-dividend date of this dividend was Thursday, May 16th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 6.10%.

Several hedge funds have recently modified their holdings of the company. Freestone Capital Holdings LLC purchased a new position in Petmed Express during the first quarter valued at $22,780,000. Capital Investment Advisory Services LLC purchased a new position in Petmed Express during the fourth quarter valued at $26,000. Fifth Third Bancorp raised its stake in Petmed Express by 288.2% during the first quarter. Fifth Third Bancorp now owns 1,650 shares of the company’s stock valued at $38,000 after buying an additional 1,225 shares during the last quarter. Manchester Capital Management LLC raised its stake in Petmed Express by 185.8% during the first quarter. Manchester Capital Management LLC now owns 1,938 shares of the company’s stock valued at $44,000 after buying an additional 1,260 shares during the last quarter. Finally, Financial Gravity Wealth Inc. purchased a new position in Petmed Express during the first quarter valued at $49,000. Hedge funds and other institutional investors own 99.65% of the company’s stock.

Petmed Express Company Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Read More: What defines an oversold asset?

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.